Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, including gefitinib, are first-line drugs against advanced non-small cell lung cancer with activating EGFR mutations. However, the development of resistance to such drugs is a major clinical challenge. METHODS: The role...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jian, Chang, Meijia, Li, Jing, Fang, Tao, Hu, Jie, Bai, Chunxue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963077/
https://www.ncbi.nlm.nih.gov/pubmed/29784046
http://dx.doi.org/10.1186/s12931-018-0804-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963077/
https://www.ncbi.nlm.nih.gov/pubmed/29784046
http://dx.doi.org/10.1186/s12931-018-0804-1

Ejemplares similares